PMID- 18622914
OWN - NLM
STAT- MEDLINE
DCOM- 20080829
LR  - 20151119
IS  - 0040-5930 (Print)
IS  - 0040-5930 (Linking)
VI  - 65
IP  - 4
DP  - 2008 Apr
TI  - [Use of trastuzumab in the therapy of breast cancer].
PG  - 217-22
LID - 10.1024/0040-5930.65.4.217 [doi]
AB  - Trastuzumab (Herceptin) is a humanized monoclonal antibody recognizing the human 
      epidermal growth factor receptor-2 (HER-2/neu). This receptor is overexpressed in 
      20-30% of invasive breast carcinomas. HER-2/neu normally regulates cell growth 
      and survival, and overexpression leads to increased signaling and thus to 
      malignant transformation and growth. HER-2/neu overexpression used to confer a 
      worse prognosis, as these tumors respond poorly to a variety of chemo- and 
      hormonal therapies. The invention of targeted therapies against the HER-2/neu 
      receptor changed this picture. Trastuzumab binds to HER-2/neu close to the cell 
      membrane and inhibits signal transduction, as well as leading to receptor 
      degradation and immune-mediated attack against the tumor cells. It was shown to 
      be effective and safe in several clinical trials, and approved for use in humans. 
      The most important adverse effect is cardiotoxicity, leading to a risk of 
      congestive heart failure in some patients, especially those pretreated with 
      anthracyclines. As this risk is low, adjuvant trastuzumab therapy was 
      investigated and showed very positive results. The addition of trastuzumab to 
      adjuvant chemotherapy consistently resulted in significant increases of both 
      disease-free and overall survival. Therefore, trastuzumab should nowadays be 
      applied to all eligible patients, i.e. patients whose tumor over-expresses 
      HER-2/neu with a immunostaining intensity of 3+ or shows HER-2/neu gene 
      amplification as demonstrated by fluorescence in situ hybridization (FISH), and 
      who do not have other contraindications. This article highlights the results of 
      pertinent clinical trials and discusses current knowledge on the optimal use of 
      trastuzumab.
FAU - Riemer, Angelika B
AU  - Riemer AB
AD  - Klinische Abteilung fur Onkologie, Universitatsklinik fur Innere Medizin I, 
      Medizinische Universitat Wien, Wahringer Gurtel 18-20, Vienna.
FAU - Zielinski, Christoph C
AU  - Zielinski CC
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Der Einsatz von Trastuzumab in der adjuvanten und palliativen Therapie des 
      Mammakarzinoms.
PL  - Switzerland
TA  - Ther Umsch
JT  - Therapeutische Umschau. Revue therapeutique
JID - 0407224
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Antibodies, Monoclonal/adverse effects/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Breast Neoplasms/*drug therapy/genetics/surgery
MH  - Chemotherapy, Adjuvant
MH  - Clinical Trials as Topic
MH  - Disease-Free Survival
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - *Palliative Care
MH  - Receptor, ErbB-2/antagonists & inhibitors/genetics
MH  - Trastuzumab
RF  - 27
EDAT- 2008/07/16 09:00
MHDA- 2008/08/30 09:00
CRDT- 2008/07/16 09:00
PHST- 2008/07/16 09:00 [pubmed]
PHST- 2008/08/30 09:00 [medline]
PHST- 2008/07/16 09:00 [entrez]
AID - 10.1024/0040-5930.65.4.217 [doi]
PST - ppublish
SO  - Ther Umsch. 2008 Apr;65(4):217-22. doi: 10.1024/0040-5930.65.4.217.